Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.